Dr. Anthony on Spartalizumab in NETs

Lowell B. Anthony, MD, FACP
Published: Thursday, May 23, 2019



Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses preliminary research with spartalizumab (PDR001) in neuroendocrine tumors (NETs).

An ongoing area of research in this space is immunotherapy. In a phase II study (NCT02955069) presented at the 2018 ESMO Congress, the safety and efficacy of spartalizumab was examined in patients with advanced NETs. Data indicated a benefit for those with thoracic NETs, says Anthony.

Spartalizumab is a PD-L1/2 inhibitor and a monoclonal antibody. The agent has been tested in prospective randomized trials in not only 3 primary sites, but also in nondifferentiated NETs, says Anthony. From the phase II trial that was done, investigators now know that responses were more pronounced in these thoracic primaries. Historically, another trial with pembrolizumab (Keytruda) showed response rates around 6% to 12%. However, it is not entirely clear whether this will translate to practice as these are early signals, concludes Anthony.
SELECTED
LANGUAGE


Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses preliminary research with spartalizumab (PDR001) in neuroendocrine tumors (NETs).

An ongoing area of research in this space is immunotherapy. In a phase II study (NCT02955069) presented at the 2018 ESMO Congress, the safety and efficacy of spartalizumab was examined in patients with advanced NETs. Data indicated a benefit for those with thoracic NETs, says Anthony.

Spartalizumab is a PD-L1/2 inhibitor and a monoclonal antibody. The agent has been tested in prospective randomized trials in not only 3 primary sites, but also in nondifferentiated NETs, says Anthony. From the phase II trial that was done, investigators now know that responses were more pronounced in these thoracic primaries. Historically, another trial with pembrolizumab (Keytruda) showed response rates around 6% to 12%. However, it is not entirely clear whether this will translate to practice as these are early signals, concludes Anthony.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Consultations®: Discussing the Nurse's Role in Treating and Managing Advanced Pancreatic AdenocarcinomaSep 28, 20191.5
Publication Bottom Border
Border Publication
x